Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Blue Jet Healthcare shares rally 9% after Rs 800 crore QIP allotment
Blue Jet Healthcare shares rose sharply on Friday after the company completed its Rs 800 crore QIP, attracting marquee institutional investors, including multiple ICICI Prudential Mutual Fund schemes. The fund raise is expected to strengthen the company's balance sheet, support expansion plans, and boost long-term growth prospects while broadening its institutional shareholder base.

Stocks to buy or sell: Dharmesh Shah of ICICI Sec suggests buying Shriram Finance, Piramal Pharma shares on 6 July
Indian benchmark indices, Sensex and Nifty 50, opened higher on July 6, driven by gains in private banking stocks following strong quarterly updates from HDFC Bank and Axis Bank. Market breadth was positive with 14 of the 16 major indices in the green.
Analysts back buy-on-dips strategy as Nifty targets 24,450–24,800
Indian stock market analysts are optimistic, anticipating the Nifty to continue its upward trend. They suggest buying on dips around the 24,000-24,150 mark, with potential upside targets reaching 24,800. Several stocks, including Container Corporation of India, IndusInd Bank, Biocon, HDFC Asset Management Company, Shriram Finance, and Piramal Pharma, are highlighted as strong buy recommendations with specific price targets and stop-losses.
Benchmarks gain for third day on positive global cues; Nifty closes at 24,271
Key benchmark indices extended gains for a third consecutive session on Friday, supported by positive global cues. Weaker-than-expected US jobs data strengthened expectations of a Federal Reserve interest rate cut at its upcoming policy meeting. The Nifty closed at 24,270.85, led by gains in IT, healthcare and metal stocks. However, profit booking in the second half trimmed intraday gains, while broader markets lagged the benchmark indices.
Market wrap: Sensex falls 250 points, Nifty closes below 23,900 on monthly expiry day
Indian equities ended lower for the second straight session as benchmarks slipped on expiry-day volatility, though broader markets advanced. IT stocks led declines amid rate worries, while auto and consumption names gained. Analysts expect sectoral rotation ahead of earnings, with banking, healthcare and power seen as resilient drivers of performance.

Healthcare, banks and EVs remain long-term bets: Invesco Mutual Fund's Taher Badshah
Taher Badshah, Chief Investment Officer at Invesco Mutual Fund, expects EV adoption to increase gradually with policy support, while opportunities are emerging in power distribution alongside transmission. Badshah also said SIP inflows remain stable and mutual fund industry trends are not showing signs of concern.
HDFC Mutual Fund buys additional 10 lakh shares of Global Health for Rs 130 crore
HDFC Mutual Fund has secured an additional 10 lakh shares of Global Health, which is known for operating Medanta hospitals, from co-founder Sunil Sachdeva for Rs 130 crore. This acquisition builds on a prior purchase made last month. The transaction accounts for a 0.37% stake in the company. In related news, Global Health has reported an impressive 39.7% increase in its fourth-quarter profit after tax, totaling Rs 141.7 crore.
Tech-Led global selloff, Fed rate fears weigh on Indian equities
Indian stock markets experienced their sharpest single-day drop in nearly a month, mirroring a global tech sell-off. The Nifty 50 and BSE Sensex both fell significantly, influenced by a strong US dollar and profit-taking after recent gains. While pharma and healthcare sectors showed resilience, most others, including metals and IT, declined. Market volatility increased, with analysts watching key support levels closely.
HDFC MF, ADIA among buyers as Sepia Investments offloads Rs 749 crore in Corona Remedies via block deal
Sepia Investments and Anchor Partners sold shares worth about Rs 777 crore in Corona Remedies through block deals. HDFC Mutual Fund emerged as the largest buyer, while several institutional investors, including Aberdeen entities, ADIA, Invesco and WhiteOak, also accumulated stakes.
PE investor BC Investments sells Rs 612 crore stake in Emcure Pharma; Kotak MF picks up stake
Private equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per share. Despite this divestment, analysts remain positive on Emcure's growth outlook across its core therapeutic segments.
Sebi may widen 50% overlap rule to thematic passive mutual fund schemes
Curb on number of smart-beta schemes also likely; move aimed at curbing proliferation in segment

Ajanta Pharma promoter sells ₹1,024 crore stake; mutual funds step in as buyers
A promoter entity of Ajanta Pharma has sold a 2.8% stake in the drugmaker for over ₹1,000 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund emerging as the key buyers.